Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has completed the acquisition of GSK’s manufacturing site in Rockville, Maryland. This transaction marks the South Korean firm’s first operational manufacturing footprint within the United States.
Operational Capacity and Scale:
-
Facility Specifications: The Rockville site features two cGMP-compliant manufacturing plants with a combined drug substance capacity of 60.000 liters. It is equipped to handle both clinical-stage and commercial-scale biologics production.
-
Global Expansion: This acquisition boosts Samsung Biologics’ total worldwide manufacturing capacity to 845.000 liters.
-
Workforce Integration: More than 500 local employees at the Maryland facility are set to transition into the Samsung Biologics organization.
Strategic Roadmap: Under the terms of the deal, Samsung Biologics will continue to supply GSK’s existing products manufactured at the site while expanding its operations to meet broader contract manufacturing demands. The company plans further technological upgrades and capacity expansions at the facility, reinforcing its commitment to a resilient global supply chain and broader patient access to essential therapies.